Regeneron Pharmaceuticals Inc. buy HSBC Holdings plc
Start price
24.11.25
/
50%
€662.20
Target price
24.11.26
€221.52
Performance (%)
-3.53%
Price
17.04.26
€637.90
Summary
This prediction is currently active. With a performance of -3.53%, the BUY prediction by HSBC_Holdings_plc is trending in the wrong direction. A total of €0.94 was paid as dividends for this prediction. This prediction currently runs until 24.11.26. The prediction end date can be changed by HSBC_Holdings_plc at any time. HSBC_Holdings_plc has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | -0.125% | -0.125% |
| iShares Core DAX® | 3.593% | 3.931% |
| iShares Nasdaq 100 | 5.810% | 5.518% |
| iShares Nikkei 225® | 4.075% | 8.460% |
| iShares S&P 500 | 4.142% | 4.039% |
Comments by HSBC_Holdings_plc for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals (NASDAQ:REGN) is now covered by analysts at HSBC Holdings plc. They set a "buy" rating and a $255.00 price target on the stock.
Ratings data for REGN provided by MarketBeat